Renal impairment (creatine clearance < 60 mL/min) has been associated with higher risk of stroke and bleeding (by almost 60%) in anticoagulated patients with arterial fibrillation (AF). Therefore, it is important for any clinician to administer medicines that can give better renal outcomes in these patients. However, there are limited data regarding the impact on renal function in patients with AF.
In this regard, a recent study evaluated the effect of warfarin or non-vitamin K antagonist oral anticoagulants (NOAC) like apixaban, dabigatran, and rivaroxaban on 4 renal outcomes such as: Declines in estimated glomerular filtration rate (eGFR) ≥30% Doubling of the serum creatinine level Acute kidney injury (AKI) Renal failure. Key clinical findings The investigators identified 9,769 patients with nonvalvular AF who started taking an oral anticoagulant agent between October 1, 2010, and…
